282 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Merck Gets Priority Review for Yet Another Keytruda sBLA http://www.zacks.com/stock/news/322981/merck-gets-priority-review-for-yet-another-keytruda-sbla?cid=CS-ZC-FT-322981 Sep 13, 2018 - Merck's (MRK) sBLA to include overall survival data from a key lung cancer study on Keytruda's label gets FDA's priority review. If approved, it will expand the eligible patient population.
Roche to Create Companion Diagnostic Test for Merck's Keytruda http://www.zacks.com/stock/news/342512/roche-to-create-companion-diagnostic-test-for-mercks-keytruda?cid=CS-ZC-FT-342512 Dec 12, 2018 - Roche (RHHBY) signs collaboration agreement with Merck for developing a companion diagnostic test to identify patients for treatment with the latter's Keytruda.
Incyte (INCY) Collaborates with Innovent for 3 Candidates http://www.zacks.com/stock/news/343302/incyte-incy-collaborates-with-innovent-for-3-candidates?cid=CS-ZC-FT-343302 Dec 17, 2018 - Incyte (INCY) collaborates with Innovent for the development of three clinical-stage product candidates: pemigatinib, itacitinib and parsaclisib.
Merck's sBLA for Keytruda in Lung Cancer Gets Extended Review http://www.zacks.com/stock/news/344112/mercks-sbla-for-keytruda-in-lung-cancer-gets-extended-review?cid=CS-ZC-FT-344112 Dec 21, 2018 - FDA extends review period for label expansion application for Merck's (MRK) Keytruda in first-line lung cancer by three months. A decision is now expected in April 2019.
Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan http://www.zacks.com/stock/news/345648/merck-buys-nash-candidate-keytruda-wins-5-approvals-in-japan?cid=CS-ZC-FT-345648 Jan 04, 2019 - Merck (MRK) exercises option to in-license an insulin sensitizer from NGM Biopharmaceuticals for NASH and type II diabetes. Its key drug Keytruda snaps up five new label expansion nods in Japan.
Is a Disappointment in Store for Incyte (INCY) Q4 Earnings? http://www.zacks.com/stock/news/353654/is-a-disappointment-in-store-for-incyte-incy-q4-earnings?cid=CS-ZC-FT-353654 Feb 11, 2019 - Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer http://www.zacks.com/stock/news/353843/mercks-keytruda-gets-fda-priority-review-for-head-neck-cancer?cid=CS-ZC-FT-353843 Feb 12, 2019 - Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/354853/incyte-incy-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-354853 Feb 14, 2019 - Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica http://www.zacks.com/stock/news/359403/zackscom-featured-expert-kevin-matras-highlights-incyte-amc-entertainment-covanta-and-us-silica?cid=CS-ZC-FT-359403 Mar 14, 2019 - Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica
4 Toxic Stocks to Abandon or Sell Short for Solid Gains http://www.zacks.com/stock/news/366679/4-toxic-stocks-to-abandon-or-sell-short-for-solid-gains?cid=CS-ZC-FT-366679 Mar 29, 2019 - Overpriced toxic stocks are generally susceptible to outside shocks and burdened with a huge amount of debt.

Pages: 1...212223242526272829

<<<Page 26>